secwatch / observer
8-K filed May 6, 2026, 7:59 PM ET ticker LFVN CIK 0000849146
earnings confidence high sentiment negative materiality 0.80

LifeVantage Q3 revenue drops 25%; EPS falls to $0.11; guidance lowered

Lifevantage Corp

2026-Q3 EPS reported $0.30 revenue$140,209,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Lifevantage Corp reported the three months ended March 31, 2026 results: revenue $43.7 million, net income $1.4 million, EPS $0.11 per diluted share. Guidance lowered.

Period
the three months ended March 31, 2026
Revenue
$43.7 million
Net income
$1.4 million
EPS
$0.11 per diluted share
Guidance
lowered
Result
reported results
Exact text from the filing
For the third quarter ended March 31, 2026, the Company reported revenue of $43.7 million, a 25.2% decrease compared to revenue of $58.4 million in the third quarter of fiscal 2025. Revenue in the Americas region for the third quarter of fiscal 2026 decreased 28.9% primarily due to declines in sales of the MindBody GLP-1 System Ò , partially offset by sales of LoveBiome, which the Company acquired in October 2025. Revenue in the Asia/Pacific & Europe region decreased 7.7%; on a constant currency basis, revenue in the Asia/Pacific & Europe region decreased approximately 8.9%. Gross profit for the third quarter of fiscal 2026 was $34.5 million, or 79.0% of revenue, compared to $47.3 million, or 81.0% of revenue, for the same period in fiscal 2025. The decrease in gross profit as a percentage of revenue was primarily due to an allowance for inventory obsolescence related to the MindBody GLP-1 System Ò , along with increases in shipping and warehouse related expenses. Adjusted for the allo
View on SEC.gov

Browse all earnings releases →

Lifevantage Corp filing history →

Source: SEC EDGAR
accession 0001193125-26-208934
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.